Cargando…

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in incomplete responders to neoadjuvant therapy. Des...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hunter, Francis W., Barker, Hilary R., Lipert, Barbara, Rothé, Françoise, Gebhart, Géraldine, Piccart-Gebhart, Martine J., Sotiriou, Christos, Jamieson, Stephen M. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054312/ https://www.ncbi.nlm.nih.gov/pubmed/31839676 http://dx.doi.org/10.1038/s41416-019-0635-y

Ejemplares similares

YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
por: Wang, Lei, et al.
Publicado: (2020)

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
por: Wang, Lei, et al.
Publicado: (2018)

The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
por: Liu, Peipei, et al.
Publicado: (2020)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
por: Corrêa, Tatiana Strava, et al.
Publicado: (2018)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
por: Girish, Sandhya, et al.
Publicado: (2012)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)
por: Chung, Yuan-Chiang, et al.
Publicado: (2015)

The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
por: Delgado, J., et al.
Publicado: (2021)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
por: Corbin, Kimberly S., et al.
Publicado: (2020)

Activity of trastuzumab emtansine (T-DM1) in 3D cell culture
por: Boyer, Jean Zheng, et al.
Publicado: (2021)

Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
por: Acibuca, Aynur, et al.
Publicado: (2021)

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
por: Diessner, J, et al.
Publicado: (2014)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Allegretti, Matteo, et al.
Publicado: (2021)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
por: Recondo, Gonzalo, et al.
Publicado: (2016)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
por: Krop, Ian E., et al.
Publicado: (2016)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
por: Moghaddas, Azadeh, et al.
Publicado: (2016)

Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial
por: Yan, Hongjing, et al.
Publicado: (2017)

Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
por: Akyildiz, Arif, et al.
Publicado: (2023)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2021)

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2022)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
por: Michel, Laura L., et al.
Publicado: (2020)

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
por: Lu, Dan, et al.
Publicado: (2014)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
por: Waks, Adrienne G, et al.
Publicado: (2022)

Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
por: Denduluri, Neelima, et al.
Publicado: (2022)

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
por: Sonnenblick, Amir, et al.
Publicado: (2015)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
por: Tang, Shou‐Ching, et al.
Publicado: (2021)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
por: Magalhães, Marcos Aurélio Fonseca, et al.
Publicado: (2022)

New generation of breast cancer clinical trials implementing molecular profiling
por: Zardavas, Dimitrios, et al.
Publicado: (2016)

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
por: Kim, Chung Young, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h9kjhhalooc034ufr95o4em155